Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is on a fast rise after it has received Health Canada approval for Essential 9TM, the first in a line of essential micronutrients products that the Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product.
Microcapdaily has been covering SBFM for many years; on April 4, 2016 we covered the stock commenting “Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making an explosive move up on accelerating volume since reversing off $0.0121 lows last week. The stock does have a history of big moves running from well under $0.25 to highs over $1.25 in 2011.
Sunshine Biopharma is pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma’s business plan includes the clinical development of Adva-27a, the Company’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma conducts its operations through three (3) wholly owned subsidiaries: Atlas Pharma Inc. (“Atlas”), a Canadian company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA.
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian company formed in 2014 for the purposes of offering generic prescription pharmaceuticals in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).
NOX Pharmaceuticals, Inc. (“NOX”) is a Colorado corporation dedicated to the research, development and commercialization of proprietary drugs including Adva27a, the Company’s flagship proprietary drug for the treatment of cancer. Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer including breast cancer cells (MCF-7/MDR), small-cell lung cancer cells (H69AR), uterine carcinoma cells (MES-SA/Dx5) and pancreatic cancer cells (Panc-1).
To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In September SBFM announced it has entered into an Equity Financing Agreement (“Equity Financing Agreement”) and Registration Rights Agreement (“Registration Rights Agreement”) with GHS Investments LLC, a Nevada limited liability company (“GHS”). Under the terms of the Equity Financing Agreement, GHS agreed to provide Sunshine with up to $10,000,000 upon effectiveness of a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission.
On December 17 SBFM announced it has received Health Canada approval for Essential 9TM, the first in a line of essential micronutrients products that the Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM are dietary supplement tablets that contain a balanced formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates to start shipping Essential 9TM in the second week of January 2019.
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in free form and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.
We have a Monster Pick Coming. Subscribe Right Now!
Currently racing up the charts SBFM has minimal asset, manageable debt and growing sales reporting $335,357 in revenues for the 9 months ended September 30, 2018. SBFM is an exciting story developing in small caps; SBFM is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of cancer. SBFM recently signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine’s lead anticancer compound targeted for Pancreatic Cancer. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.